InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,717.62
(
-0.27%
)
Post# of 251715
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dav1234

Send PM Follow Ignore
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

dav1234

Re: None

Monday, 03/31/2014 9:00:07 AM

Monday, March 31, 2014 9:00:07 AM

Post# of 251715
Glaxo pulls plug on expanded use of Votrient
After additional analysis of Phase 3 trial data, GlaxoSmithKline (GSK) decides to withdraw its European application for the use of Votrient (pazopanib) in advanced ovarian cancer.
Although initial results showed an improvement in progression-free survival, further analysis failed to show a sufficient benefit-to-risk ratio to proceed.
http://www.reuters.com/article/2014/03/31/us-glaxosmithkline-brief-idUSBREA2U0PB20140331
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up